- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02623374
MENOS@Work Trial: A Self-help CBT Intervention for Working Women
Menopause at Work: Improving the Experience of Menopause for Working Women
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
While some women go through the menopause without any problems, about 25% have troublesome symptoms that affect their daily lives. Hot flushes and night sweats are the main menopausal symptoms and cause physical discomfort, embarrassment and interfere with sleep. Menopausal symptoms have also been reported as problematic by women when at work. In the UK there are over 3.5 million working women aged between 50 and 65 (the majority of whom will be in the menopause transition or postmenopause), yet there is a general lack of awareness about menopause in work settings. Some women take hormone replacement therapy (HRT) to help them to manage working life, but many prefer non-medical options. While there are effective non-medical interventions (such as cognitive behaviour therapy) to help women to manage and cope with menopausal symptoms, these are not yet widely available on the NHS or in the workplace.
In a recent study of 896 women's experiences of working through the menopausal transition in the UK, Griffiths and colleagues (2013) found that the menopausal transition caused difficulties for them, mainly due to troublesome hot flushes, poor concentration, tiredness, poor memory, feeling low/depressed and lowered confidence. Some women were also concerned that their work performance had been negatively affected. Those who were taking HRT did so mainly to help them to cope at work but over 30% of these had side effects or felt that HRT had not helped. The majority of women were unwilling to disclose menopause-related health problems to line managers, most of whom were men or younger than them. Four major areas of need were identified: (i) greater awareness among managers about menopause as a possible occupational health issue, (ii) flexible working hours, (iii) access to information and sources of support at work, and (iv) attention to workplace temperature and ventilation. The authors concluded that employers should be aware that menopausal transition can cause difficulty for some women at work, and that much can be done to support them. The proposed research will aim to target (iii).
Hunter and colleagues (2012) have developed a brief non-medical treatment to help women to manage hot flushes and night sweats, based on cognitive behaviour therapy (CBT), to help women to manage menopausal symptoms. They have evaluated group and self-help forms of the interventions, and found them to be highly effective in reducing how problematic the symptoms are rated. Women receive information and advice to help them to develop strategies to reduce stress, to deal with hot flushes and to improve sleep disrupted by night sweats. In recent randomised controlled trials, women who received the CBT intervention benefited from improvements in hot flushes and night sweats, sleep and perception of memory and concentration, and ability to cope, resulting in benefits to quality of life compared to those who received usual care. Interestingly, the self-help CBT (containing the same information in a booklet with a relaxation CD) was as effective as the group CBT.
The proposed research builds upon these findings and aims to develop and examine the feasibility and impact of an adapted self-help CBT intervention (SHCBT) based on Hunter's early work to help management symptoms and improve the quality of life for working menopausal women.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, SE1 9RT
- King's College London
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Employed women aged 45-60 years
- Have at least 10 problematic (score >2 on HFRS) hot flushes per week for at least two months
- Have a good understanding of English
Exclusion Criteria:
- Men
- Women who cannot understand English
- Women with problematic mental health conditions that may affect participation in the study
- Women not employed (by participating organisations)
- Women outside the inclusion age range and symptom criteria.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SH-CBT
This intervention will be a tailored CBT intervention adapted from the previously validated (Ayres, et al., 2012) self-help CBT intervention that comprises of a self-help booklet containing information, advice, a relaxation CD and daily diaries.
This intervention lasts 4 weeks (approx.
4 hours per week) and the materials guide the individual through each chapter and exercise, including the homework set out for each chapter.
|
See 'Arms' section
|
No Intervention: No Treatment-Wait Control (NTWC)
Women will be offered no intervention but will complete questionnaires at the same assessment points as the intervention/treatment arm participant group (i.e.
baseline (A0), 6 weeks (A1), 20 weeks (A2) post randomisation).
They will be offered the SHCBT intervention off trial following the final assessment (i.e.
A2).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Problematic hot flushes
Time Frame: Measurements will be taken at A1 (6 weeks postrandomisation).
|
Measured using the Hot Flush Rating Scale (HFRS) by Hunter & Liao (1995), which includes a score between 1-10 based on the mean of three 3-point Likert scales (1=no problem at all, 10=very much a problem) assessing hot flushes and night sweats (HFNS) bother, interference, and distress.
|
Measurements will be taken at A1 (6 weeks postrandomisation).
|
Problematic hot flushes
Time Frame: Measurements will be taken at A2 (20 weeks postrandomisation).
|
Measured using the Hot Flush Rating Scale (HFRS) by Hunter & Liao (1995), which includes a score between 1-10 based on the mean of three 3-point Likert scales (1=no problem at all, 10=very much a problem) assessing hot flushes and night sweats (HFNS) bother, interference, and distress.
|
Measurements will be taken at A2 (20 weeks postrandomisation).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Problematic hot flushes (frequency)
Time Frame: Measurements will be taken at A1 (6 weeks postrandomisation).
|
Measured using the Hot Flush Rating Scale (HFRS) by Hunter & Liao (1995), which gives provides a retrospective recording of the frequency of HFNS and the average severity of the HFNW for the previous week (1=mild, 2=moderate, 3=severe).
|
Measurements will be taken at A1 (6 weeks postrandomisation).
|
Problematic hot flushes (frequency)
Time Frame: Measurements will be taken at A2 (20 weeks postrandomisation).
|
Measured using the Hot Flush Rating Scale (HFRS) by Hunter & Liao (1995), which gives provides a retrospective recording of the frequency of HFNS and the average severity of the HFNW for the previous week (1=mild, 2=moderate, 3=severe).
|
Measurements will be taken at A2 (20 weeks postrandomisation).
|
Menopause Representation Questionnaire (Hunter & O'Dea, 2001)
Time Frame: Measurements will be taken at A1 (6 weeks postrandomisation).
|
designed to assess women's attributions (identity) of symptoms to the menopause (20 items) and beliefs subscales (cognitive representations) about the menopause (17 items).
The belief items are scored on 5-point scales from strongly agree (5) to strongly disagree (1), and mean scores are calculated for beliefs subscales.
The identity subscale items are scored from 0 to 2 and summed.
|
Measurements will be taken at A1 (6 weeks postrandomisation).
|
Menopause Representation Questionnaire (Hunter & O'Dea, 2001)
Time Frame: Measurements will be taken at A2 (20 weeks postrandomisation).
|
designed to assess women's attributions (identity) of symptoms to the menopause (20 items) and beliefs subscales (cognitive representations) about the menopause (17 items).
The belief items are scored on 5-point scales from strongly agree (5) to strongly disagree (1), and mean scores are calculated for beliefs subscales.
The identity subscale items are scored from 0 to 2 and summed.
|
Measurements will be taken at A2 (20 weeks postrandomisation).
|
Attitude to Menopause at Work
Time Frame: Measurements will be taken at A1 (6 weeks postrandomisation).
|
This measures attitude to menopause and work and whether women feel that their job performance has been affected by menopausal symptoms, and whether they feel that menopause has negatively affected manager's and colleagues views of competence at work (Griffiths, et al., 2010).
Contains 2 items scored on 5-point scales (agree (5) to strongly disagree (1)).
|
Measurements will be taken at A1 (6 weeks postrandomisation).
|
Attitude to Menopause at Work
Time Frame: Measurements will be taken at A2 (20 weeks postrandomisation).
|
This measures attitude to menopause and work .e. whether women feel that their job performance has been affected by menopausal symptoms, and whether they feel that menopause has negatively affected manager's and colleagues views of competence at work (Griffiths, et al., 2010).
Contains 2 items scored on 5-point scales (agree (5) to strongly disagree (1)).
|
Measurements will be taken at A2 (20 weeks postrandomisation).
|
Hot Flush and Night Sweats Belief & Behaviour
Time Frame: Measurements will be taken at A1 (6 weeks postrandomisation).
|
16 items to measure beliefs about hot flushes and night sweats (HFNS) and behavioural reactions to cope with HFNS using a 6-point scale from strongly disagree (0) to strongly agree (5).
This is a shortened and combined version of Hot Flush Belief & Behaviour Scale (Rendall, et al, 2008; Hunter et al, 2011)
|
Measurements will be taken at A1 (6 weeks postrandomisation).
|
Hot Flush and Night Sweats Belief & Behaviour
Time Frame: Measurements will be taken at A2 (20 weeks postrandomisation).
|
16 items to measure beliefs about hot flushes and night sweats (HFNS) and behavioural reactions to cope with HFNS using a 6-point scale from strongly disagree (0) to strongly agree (5).
This is a shortened and combined version of Hot Flush Belief & Behaviour Scale (Rendall, et al, 2008; Hunter et al, 2011)
|
Measurements will be taken at A2 (20 weeks postrandomisation).
|
Presenteeism (Koopman et al, 2002)
Time Frame: Measurements will be taken at A1 (6 weeks postrandomisation).
|
Stanford Presenteeism Scale (SPS6, Koopman, et al 2002) is used to measure workplace presenteeism, comprises of 6 items that are summed to produce a total presenteeism score.
Each item asks the respondent to indicate their work experience over the last month using a 5-point scale (1=strongly disagree, 5=strongly agree).
|
Measurements will be taken at A1 (6 weeks postrandomisation).
|
Presenteeism (Koopman et al, 2002)
Time Frame: Measurements will be taken at A2 (20 weeks postrandomisation).
|
Stanford Presenteeism Scale (SPS6, Koopman, et al 2002) is used to measure workplace presenteeism, comprises of 6 items that are summed to produce a total presenteeism score.
Each item asks the respondent to indicate their work experience over the last month using a 5-point scale (1=strongly disagree, 5=strongly agree).
|
Measurements will be taken at A2 (20 weeks postrandomisation).
|
Workplace absence (duration)
Time Frame: Measurements will be taken at A1 (6 weeks postrandomisation).
|
Participants asked to provide detail of number of days they have taken off from work over the last 4 weeks because of the menopause.
|
Measurements will be taken at A1 (6 weeks postrandomisation).
|
Workplace absence (duration)
Time Frame: Measurements will be taken at A2 (20 weeks postrandomisation).
|
Participants asked to provide detail of number of days they have taken off from work over the last 4 weeks because of the menopause.
|
Measurements will be taken at A2 (20 weeks postrandomisation).
|
Workplace absence (spells)
Time Frame: Measurements will be taken at A1 (6 weeks postrandomisation).
|
Participants asked to provide detail of average length of spells of absence from work over the last 4 weeks because of the menopause.
|
Measurements will be taken at A1 (6 weeks postrandomisation).
|
Workplace absence (spells)
Time Frame: Measurements will be taken at A2 (20 weeks postrandomisation).
|
Participants asked to provide detail of average length of spells of absence from work over the last 4 weeks because of the menopause.
|
Measurements will be taken at A2 (20 weeks postrandomisation).
|
Workplace absence (arriving late/leaving early)
Time Frame: Measurements will be taken at A1 (6 weeks postrandomisation).
|
Participants asked to provide detail of any time over the last 4 weeks been late to work of left work early because of the menopause.
|
Measurements will be taken at A1 (6 weeks postrandomisation).
|
Workplace absence (arriving late/leaving early)
Time Frame: Measurements will be taken at A2 (20 weeks postrandomisation).
|
Participants asked to provide detail of any time over the last 4 weeks been late to work of left work early because of the menopause.
|
Measurements will be taken at A2 (20 weeks postrandomisation).
|
Menopausal symptom disclosure to manager
Time Frame: Measurements will be taken at A1 (6 weeks postrandomisation).
|
Menopausal symptom disclosure to managers is measured using a single dichotomous item ('yes' or 'no'; Griffiths, et al, 2010, 2013) and whether participants have told their manager about any reduced working hours (i.e.
arriving late, leaving early) due to their menopausal symptoms (if appropriate) 'yes', 'no', 'sometimes').
|
Measurements will be taken at A1 (6 weeks postrandomisation).
|
Menopausal symptom disclosure to manager
Time Frame: Measurements will be taken at A2 (20 weeks postrandomisation).
|
Menopausal symptom disclosure to managers is measured using a single dichotomous item ('yes' or 'no'; Griffiths, et al, 2010, 2013) and whether participants have told their manager about any reduced working hours (i.e.
arriving late, leaving early) due to their menopausal symptoms (if appropriate) 'yes', 'no', 'sometimes').
|
Measurements will be taken at A2 (20 weeks postrandomisation).
|
Turnover intentions
Time Frame: Measurements will be taken at A1 (6 weeks postrandomisation).
|
Work turnover intentions are measured with 4 items (Shore and Martin, 1980), to assess how likely the individual is to leave their organisation).
Each item contains 5 response options indicating low (1) to high (5) intentions to remain in their organisation that can be averaged to provide an overall score.
Two further items are used to measure the degree to which the individual has considered reducing their working hours or leaving the workforce altogether ('yes', 'no', 'sometimes').
|
Measurements will be taken at A1 (6 weeks postrandomisation).
|
Turnover intentions
Time Frame: Measurements will be taken at A2 (20 weeks postrandomisation).
|
Work turnover intentions are measured with 4 items (Shore and Martin, 1980), to assess how likely the individual is to leave their organisation).
Each item contains 5 response options indicating low (1) to high (5) intentions to remain in their organisation that can be averaged to provide an overall score.
Two further items are used to measure the degree to which the individual has considered reducing their working hours or leaving the workforce altogether ('yes', 'no', 'sometimes').
|
Measurements will be taken at A2 (20 weeks postrandomisation).
|
Job satisfaction
Time Frame: Measurements will be taken at A1 (6 weeks postrandomisation).
|
A single-item 7-point Likert scale (1=extremely dissatisfied, 4=neither dissatisfied or satisfied, 7=extremely satisfied) to indicate an individual's level of contentment with their job (Griffiths et al, 2010,2013).
|
Measurements will be taken at A1 (6 weeks postrandomisation).
|
Job satisfaction
Time Frame: Measurements will be taken at A2 (20 weeks postrandomisation).
|
A single-item 7-point Likert scale (1=extremely dissatisfied, 4=neither dissatisfied or satisfied, 7=extremely satisfied) to indicate an individual's level of contentment with their job (Griffiths et al, 2010,2013).
|
Measurements will be taken at A2 (20 weeks postrandomisation).
|
Job performance
Time Frame: Measurements will be taken A1 (6 weeks postrandomisation).
|
A single self-report item.
Participants are asked to rate their performance compared to others in a similar role or position to themselves usinf a 5-point Likert scale (1=poor, 5=excellent).
|
Measurements will be taken A1 (6 weeks postrandomisation).
|
Job performance
Time Frame: Measurements will be taken A2 (20 weeks postrandomisation).
|
A single self-report item.
Participants are asked to rate their performance compared to others in a similar role or position to themselves usinf a 5-point Likert scale (1=poor, 5=excellent).
|
Measurements will be taken A2 (20 weeks postrandomisation).
|
Job stress
Time Frame: Measurements will be taken at A1 (6 weeks postrandomisation).
|
A single, self-report item asking participants to indicate on a 4-point Likert scale how stressful they find their job (1=not stressful, 4=extremely stressful) (Houdmont et al, 2012).
|
Measurements will be taken at A1 (6 weeks postrandomisation).
|
Job stress
Time Frame: Measurements will be taken at A2 (20 weeks postrandomisation).
|
A single, self-report item asking participants to indicate on a 4-point Likert scale how stressful they find their job (1=not stressful, 4=extremely stressful) (Houdmont et al, 2012).
|
Measurements will be taken at A2 (20 weeks postrandomisation).
|
Perceptions of physical and emotional menopausal symptoms
Time Frame: Measurements will be taken at A1 (6 weeks postrandomisation).
|
Women's Health Questionnaire (Hunter, 1992) used to assess participant perceptions of symptoms using a 4-point Likert scale.
Includes 37 items.
|
Measurements will be taken at A1 (6 weeks postrandomisation).
|
Perceptions of physical and emotional menopausal symptoms
Time Frame: Measurements will be taken at A2 (20 weeks postrandomisation).
|
Women's Health Questionnaire (Hunter, 1992) used to assess participant perceptions of symptoms using a 4-point Likert scale.
Includes 37 items.
|
Measurements will be taken at A2 (20 weeks postrandomisation).
|
Sleep quality (Mundt, et al, 2002)
Time Frame: Measurements will be taken at A1 (6 weeks postrandomisation).
|
Single item from Pittsburgh Sleep Quality Index (PSQI) (Buysse et al., 1989) that measures quality of sleep over the last month using a 5-point likert scale (very good=5 to very bad = 1).
|
Measurements will be taken at A1 (6 weeks postrandomisation).
|
Sleep quality (Mundt, et al, 2002)
Time Frame: Measurements will be taken at A2 (20 weeks postrandomisation).
|
Single item from Pittsburgh Sleep Quality Index (PSQI) (Buysse et al., 1989) that measures quality of sleep over the last month using a 5-point likert scale (very good=5 to very bad = 1).
|
Measurements will be taken at A2 (20 weeks postrandomisation).
|
Personal resilience at work
Time Frame: Measurements will be taken at A1 (6 weeks postrandomisation).
|
Single item that measures participants' self-perceived level of resilience in the work context (Hardy et al, in prep) used using a 9-point scale (1=low resilience to 9=high resilience).
|
Measurements will be taken at A1 (6 weeks postrandomisation).
|
Personal resilience at work
Time Frame: Measurements will be taken at A2 (20 weeks postrandomisation).
|
Single item that measures participants' self-perceived level of resilience in the work context (Hardy et al, in prep) used using a 9-point scale (1=low resilience to 9=high resilience).
|
Measurements will be taken at A2 (20 weeks postrandomisation).
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Use of medical resources for menopause (visits)
Time Frame: Measurements will be taken at A2 (20 weeks postrandomisation).
|
The use of medical resources for menopause and treatments for HFNS will be monitored, to determine how often visited their GP/hospital doctor/nurse about the menopause since starting the trial.
|
Measurements will be taken at A2 (20 weeks postrandomisation).
|
Use of medical resources for menopause (treatments for HFNS)
Time Frame: Measurements will be taken at A2 (20 weeks postrandomisation).
|
The use of medical resources for treatments for HFNS will be monitored, by asking whether they have/are currently taking any treatment (medical or non-medical) for HFNS (dichotomous: yes/no).
|
Measurements will be taken at A2 (20 weeks postrandomisation).
|
Adherence, acceptability and feasibility of intervention: completion
Time Frame: Measurements will be taken at A1 (6 weeks postrandomisation).
|
Question about how much of the booklet they read using a 4-point likert scale (not at all - all of it).
|
Measurements will be taken at A1 (6 weeks postrandomisation).
|
Adherence, acceptability and feasibility of intervention: completion
Time Frame: Measurements will be taken at A2 (20 weeks postrandomisation).
|
Question about how much of the booklet they read using a 4-point likert scale (not at all - all of it).
|
Measurements will be taken at A2 (20 weeks postrandomisation).
|
Adherence, acceptability and feasibility of intervention: changes in coping
Time Frame: Measurements will be taken at A1 (6 weeks postrandomisation).
|
Six items using a 5-point Likert scale (1=not at all to 5 =extremely) asking whether the guide has affected their management of dealing with stress and coping in the past 4 weeks.
|
Measurements will be taken at A1 (6 weeks postrandomisation).
|
Adherence, acceptability and feasibility of intervention: changes in coping
Time Frame: Measurements will be taken at A2 (20 weeks postrandomisation).
|
Six items using a 5-point Likert scale (1=not at all to 5 =extremely) asking whether the guide has affected their management of dealing with stress and coping in the past 4 weeks.
|
Measurements will be taken at A2 (20 weeks postrandomisation).
|
Adherence, acceptability and feasibility of intervention: relaxation and breathing
Time Frame: Measurements will be taken at A1 (6 weeks postrandomisation).
|
4 items using 5-point scales to evaluate the relaxation and breathing exercises.
|
Measurements will be taken at A1 (6 weeks postrandomisation).
|
Adherence, acceptability and feasibility of intervention: relaxation and breathing
Time Frame: Measurements will be taken at A2 (20 weeks postrandomisation).
|
4 items using 5-point scales to evaluate the relaxation and breathing exercises.
|
Measurements will be taken at A2 (20 weeks postrandomisation).
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Myra S Hunter, PhD, King's College London
Publications and helpful links
General Publications
- Hardy C, Griffiths A, Norton S, Hunter MS. Self-help cognitive behavior therapy for working women with problematic hot flushes and night sweats (MENOS@Work): a multicenter randomized controlled trial. Menopause. 2018 May;25(5):508-519. doi: 10.1097/GME.0000000000001048.
- Hunter MS, Hardy C, Norton S, Griffiths A. Study protocol of a multicentre randomised controlled trial of self-help cognitive behaviour therapy for working women with menopausal symptoms (MENOS@Work). Maturitas. 2016 Oct;92:186-192. doi: 10.1016/j.maturitas.2016.07.020. Epub 2016 Jul 29.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- WOW-RG1701
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Menopause
-
Riphah International UniversityCompleted
-
Englewood Hospital and Medical CenterNanohealth, Inc.WithdrawnMenopause SymptomsUnited States
-
Englewood Hospital and Medical CenterNanohealth, Inc.CompletedMenopause SymptomsUnited States
-
University of Colorado, DenverCompletedMenopause | Pre-menopauseUnited States
-
S.LAB (SOLOWAYS)Center of New Medical TechnologiesCompletedMenopause SymptomsRussian Federation
-
BHR Pharma, LLCTerminatedMenopause Related ConditionsGermany
-
Singapore General HospitalRecruitingMenopause | Menopause Related ConditionsSingapore
-
University of ArkansasRecruitingMenopause Related ConditionsUnited States
-
Wake Forest University Health SciencesWithdrawnMenopause Related Conditions
-
I.M. Sechenov First Moscow State Medical UniversityCompletedMenopause Related ConditionsRussian Federation
Clinical Trials on self-help CBT intervention (SHCBT)
-
Chinese University of Hong KongNot yet recruitingDepression | Insomnia
-
Chinese University of Hong KongNot yet recruiting
-
Karolinska InstitutetRegion StockholmCompletedAnxiety Disorders | Major Depression | Primary Insomnia | Stress DisordersSweden
-
Linnaeus UniversityKronoberg County Council; Capio GroupCompletedQuality of Life | Stress | Insomnia | Psychological Distress | Depression, Anxiety | Activities, Daily LivingSweden
-
Kaiser PermanenteOregon Health and Science UniversityCompleted
-
Karolinska InstitutetStiftelsen Professor Bror Gadelius MinnesfondCompleted
-
University Health Network, TorontoCentre for Addiction and Mental Health; The Ottawa Hospital; Ryerson University; Humber River Hospital and other collaboratorsRecruitingObesity | Mental Health Disorder | Bariatric Surgery Candidate | Eating DisordersCanada
-
University of EdinburghUnknownDepression | Anxiety | Type 2 DiabetesUnited Kingdom
-
University of CologneEli Lilly and CompanyCompletedAttention-Deficit/Hyperactivity DisorderGermany